trial · primary record
High-dose Methotrexate (8 gm/m2; HD-MTX)
Metastatic Breast Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 16 |
| Primary completion | 2027-07 |
| Primary endpoint | Overall Survival (at 12 weeks) |
| Registry ID | NCT02422641 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:30:48.322Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02422641
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.